AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9257749
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg intravenously twice a day for 4 days and Sucralfate 2 g orally three times a day for 7 days (Group A)
Trial: 8292694
Drug: No neuroendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neuroendocrine tests administered
Trial: 3802690
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release oral morphine sulphate (MS-Contin)
Trial: 3802690
Drug: Solution of
RxNorm normalized name: Solution of protein-free hemodialysate of calf blood
DrugBank: SM-1997 (DB18670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of oral morphine sulphate
Trial: 30595364
Drug: Melatonin 25
RxNorm normalized name: calcium phosphate/melatonin 250 mg-1.5 mg ORAL TABLET,CHEWABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 25 mg/d for 6 months
Trial: 26498427
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml 0.4% CHO ingested serially via 25 ml boluses
Trial: 26498427
Drug: 375 ml
RxNorm normalized name: isopropyl alcohol 0.0375 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 ml 0% CHO control (CON) ingested followed by one 25 ml 6% CHO mouth rinse
Trial: 31987231
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg)
Trial: 23657486
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (50 mg)
Trial: 22407780
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of curcumin and diclofenac sodium
Trial: 15992643
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day simvastatin (aggressive therapy)
Trial: 15992643
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (20 mg and 80 mg simvastatin)
Trial: 15992643
Drug: Patients reaching
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients reaching mean on-treatment LDL-C < or = 100 mg/dl
Trial: 2185822
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg
Trial: 2185822
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg
Trial: 18978102
Drug: Mifepristone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 10 mg
Trial: 1986952
Drug: Luteal support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal support therapy (intramuscular injections of progesterone and/or human chorionic gonadotropin)
Trial: 3916369
Drug: Pentaerythritol tetranicotinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerythritol tetranicotinate (Perycit) 750 mg daily
Trial: 23166343
Drug: Continuous-infusion doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks over 48 hours)
Trial: 23166343
Drug: Bolus-infusion doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks within 15 minutes)
Trial: 8450994
Drug: Azathioprine 2
RxNorm normalized name: azathioprine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 2 to 2.5 mg/kg/d
Trial: 3708119
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg furosemide tablet (Product 1)
Trial: 3708119
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg furosemide tablet (Product 2)
Trial: 27687681
Drug: Constant dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant dose, 4500 SW at 20 kV
Trial: 27687681
Drug: Dose reduction,
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction, 1500 SW at 22 kV, followed by 1500 SW at 20 kV and then 1500 SW at 18 kV
Trial: 26117944
Drug: Qilin Pills
RxNorm normalized name: Qilib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilin Pills (6 g, bid)
Trial: 26117944
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg, qd)
Trial: 26117944
Drug: Qilin Pills
RxNorm normalized name: Qilib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilin Pills plus sertraline
Trial: 24620654
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined radiotherapy (34 patients)
Trial: 24620654
Drug: Chemotherapy (23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (23 patients)
Trial: 21455074
Drug: Neostigmine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine group (neostigmine 20 μg kg‐1)
Trial: 19878605
Drug: Conventional time-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional time-based Green Prescription
Trial: 16483622
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (10 consecutive daily i.v. injections of 2.16 mg/kg)
Trial: 16483622
Drug: Regimen C
RxNorm normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C (graded dosing: 1.8, 2.16, 2.52, 2.52, 2.88, 3.24, then 3.6 mg/kg for the last three injections)
Trial: 10839903
Drug: 2.5 microg
RxNorm normalized name: Digoxin 62.5 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 microg sufentanil combined with 2.5 mg bupivacaine
Trial: 10839903
Drug: 5.0 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 microg sufentanil combined with 2.5 mg bupivacaine
Trial: 10839903
Drug: 10.0 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 microg sufentanil combined with 2.5 mg bupivacaine
Trial: 10839903
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 microg sufentanil combined with 2.5 mg bupivacaine)
Trial: 9352866
Drug: Isosorbide-5-mononitrate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (20 mg three times daily)
Trial: 25429853
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg
Trial: 11570381
Drug: Maze procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maze procedure with SICTRA (20 to 32 W; 200 to 320 mL/h saline)
Trial: 9551875
Drug: Irbesartan 75
RxNorm normalized name: irbesartan 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 75 mg once daily
Trial: 4026908
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once daily
Trial: 7941939
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine 0.5% 2.5 mg kg‐1
Trial: 2896555
Drug: ICI 118,551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551 10 mg
Trial: 2896555
Drug: ICI 118,551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551 100 mg
Trial: 27382814
Drug: Pentazocine with
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentazocine with rectal diclofenac (100mg diclofenac suppository and 30mg intramuscular pentazocine)
Trial: 27382814
Drug: Pentazocine alone
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentazocine alone (30mg intramuscular pentazocine)
Trial: 16368878
Drug: Effective antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective antiretroviral therapy (ART)
Trial: 21797916
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal gel and placebo pills
Trial: 12169076
Drug: Hand-rubbing protocol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand-rubbing protocol with 75% aqueous alcoholic solution containing propanol‐1, propanol‐2, and mecetronium etilsulfate
Trial: 12169076
Drug: Hand-scrubbing protocol
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand-scrubbing protocol with antiseptic preparation containing 4% povidone iodine or 4% chlorhexidine gluconate
Trial: 3279748
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (10 mg/d)
Trial: 20960028
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day, Schedule 2/1) + Pemetrexed (500 mg/m2)
Trial: 20960028
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg/day, continuous daily dosing) + Pemetrexed (500 mg/m2)
Trial: 17490489
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg once daily for 12 weeks
Trial: 17490489
Drug: Bendroflumethiazide 2.5
RxNorm normalized name: bendroflumethiazide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 2.5 mg once daily for 12 weeks
Trial: 15658072
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of intranasal butorphanol (treatment B)
Trial: 15658072
Drug: Intranasal butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal butorphanol (1 mg and 2 mg)
Trial: 15658072
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (1 mg, 2 mg intranasal, and 2 mg i.v.)
Trial: 11055460
Drug: Methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.3 mg/kg per dose)
Trial: 8398318
Drug: Infusional FEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusional FEC (5‐fluorouracil 200 mg/m2 i.v. 24 hourly by continuous infusion for 6 months, epirubicin 50 mg/m2 i.v. bolus once every 3 weeks for 6 months, cisplatin 60 mg/m2 i.v. once every 3 weeks for 6 months)
Trial: 3131943
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg mitomycin C (MMC) instilled for 0.5 hours
Trial: 3131943
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg mitomycin C (MMC) instilled for 1.0 hours
Trial: 3131943
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg mitomycin C (MMC) instilled for both 0.5 and 1.0 hours
Trial: 29136032
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with VL 1,000-5,000 copies/ml
Trial: 17961560
Drug: 100 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg/day E(2) patch, oral medroxyprogesterone acetate 10 mg for 12 days each month for patients
Trial: 10908898
Drug: Levetiracetam 1000
RxNorm normalized name: levetiracetam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1000 mg/day
Trial: 17129331
Drug: Nurse practitioners
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment for 16 weeks
Trial: 17129331
Drug: Nurse practitioners
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment
Trial: 9062610
Drug: metoclopramide 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 0.15 mg/kg
Trial: 16178945
Drug: Sumatriptan 50
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 50 mg
Trial: 20608995
Drug: Rosuvastatin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin at 2.5 mg/day (ROSUVA, n = 11)
Trial: 16569825
Drug: Gatifloxacin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin monotherapy
Trial: 11207516
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (400 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Trial: 11207516
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Trial: 9049575
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion at 30 micrograms.kg‐1.min‐1 (group I)
Trial: 9049575
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion at 5 micrograms.kg‐1.min‐1 (group II)
Trial: 2873396
Drug: Cyclosporin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin 7.5 mg/kg per day
Trial: 31910992
Drug: Lower target
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower target glycemic control (80-100 mg/dL)
Trial: 31910992
Drug: Higher target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher target glycemic control (150-180 mg/dL)
Trial: 19176440
Drug: Symptom-guided therapy
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-guided therapy
Trial: 21959480
Drug: Acetaminophen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (40 mg/kg) plus diclofenac (1 mg/kg)
Trial: 18240925
Drug: Spinal cord
RxNorm normalized name: BOS TAURUS SPINAL CORD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal cord stimulation (SCS) + physical therapy (PT)
Trial: 22502793
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) alone
Trial: 17361530
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with combination of acupuncture (HANS) and enflurane
Trial: 31430830
Drug: Single-session Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session Acceptance and Commitment Therapy (ACT) intervention
Trial: 26075381
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and Acceptance and commitment therapy (ACT)
Trial: 14749563
Drug: Oxandrolone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.1 mg/kg by mouth twice daily)
Trial: 11273789
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg orally, twice daily)
Trial: 9624308
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sublingual melatonin
Trial: 8895290
Drug: Droperidol 0.625
RxNorm normalized name: droPERidol 0.625 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.625 mg IV plus Metoclopramide 10 mg IV (Group DM)
Trial: 25256137
Drug: MS-20 for
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MS-20 for 1 week followed by 3 weeks of concomitant MS-20 plus chemotherapy
Trial: 25256137
Drug: MS-20 treatment
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MS-20 treatment
Trial: 25256137
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for 3 weeks
Trial: 21095627
Drug: Oral ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ivabradine for 5 days prior to CTCA
Trial: 21095627
Drug: Chronic beta-blockade
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic beta-blockade (atenolol 50mg twice a day for 5 days prior to CTCA)
Trial: 18053198
Drug: Merional administered
RxNorm normalized name: Meriones unguiculatus skin
DrugBank: Meriones unguiculatus skin (DB10603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merional administered subcutaneously (s.c.)
Trial: 18053198
Drug: Merional administered
RxNorm normalized name: Meriones unguiculatus skin
DrugBank: Meriones unguiculatus skin (DB10603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merional administered intramuscularly (i.m.)
Trial: 8996744
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 450 mg clindamycin (CLDM) three times daily for 7 days
Trial: 8996744
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 2% CLDM phosphate in cream (self-made) 5 g once a day for 7 days
Trial: 8996744
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 450 mg CLDM
Trial: 8217999
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 50 mg/day (n = 103)
Trial: 25057035
Drug: GnRH+ (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH+ (100 μg GnRH)
Trial: 20395554
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (n = 60)
Trial: 7782725
Drug: Arabica oil
RxNorm normalized name: arabica coffee oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arabica oil (2 g per day)
Trial: 7782725
Drug: Robusta oil
RxNorm normalized name: Shorea robusta resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robusta oil (2 g per day)
Trial: 6414821
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg b.d. (oral)
Trial: 6414821
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 20 mg q.i.d. (inhalation)
Trial: 31718678
Drug: Treat-to-target (T2T)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treat-to-target (T2T) therapy aimed at DAS28-ESR remission
Trial: 29268805
Drug: Reason for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reason for discontinuation of breast-feeding due to conflict stress
Trial: 24476987
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge (4 mg) with expectancy
Trial: 18198648
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SFI), antibiotics, and short-term pulse therapy with high efficient hormone
Trial: 18198648
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and hormone pulse therapy
Trial: 16402538
Drug: Oral pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pioglitazone (15 mg to 45 mg)
Trial: 9502570
Drug: Glucose-charged dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-charged dialysate (9.17 mmol/l or 165 mg/dl)
Trial: 10551383
Drug: Interferon-alpha treatment
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha treatment
Trial: 2757899
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of cilazaprilat
Trial: 25800548
Drug: ACE‐I/ARB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE‐I/ARB treatment
Trial: 7969680
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment
Trial: 18070786
Drug: Hyperbaric articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric articaine 80 mg
Trial: 19548294
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg daily
Trial: 16960699
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg daily
Trial: 14501737
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg daily
Trial: 15647704
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy
Trial: 9090340
Drug: Medication (fluoxetine)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (fluoxetine) plus psychological treatment
Trial: 9090340
Drug: Supportive psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive psychotherapy plus medication
Trial: 9090340
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus psychological treatment
Trial: 31574303
Drug: Transcatheter mitral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter mitral valve repair (TMVr) plus maximally tolerated guideline-directed medical therapy (GDMT)
Trial: 10559567
Drug: Denbufylline 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denbufylline 25, 50 or 100 mg
Trial: 31532795
Drug: High-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omega-3 fatty acids (O-3FA) for 6 months